Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01638247
Other study ID # GBG 54
Secondary ID 2009-015122-11
Status Completed
Phase Phase 3
First received
Last updated
Start date August 2012
Est. completion date May 2018

Study information

Verified date September 2018
Source German Breast Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (MALE).


Description:

Breast cancer in men is a rare disease with approximately 0.5- 1% of all breast cancer cases. Each year, about 400 to 450 cases are diagnosed in Germany. Men tend to present with more advanced disease than women, probably due to the lack of awareness of male breast cancer from both, the patient and the physicians.

Therefore, at presentation they usually have lump or nipple inversion, and more than 40% of the patients have a stage III or IV disease. The great majority of patients have an invasive ductal (90%), hormone receptor positive (90%), HER2 negative (90%) tumor.

The only available information on adjuvant therapies derives from few retrospective cases and retrospective studies with a little number of cases. Therefore, treatment strategies are not based on data from prospective, randomised clinical studies, and optimal treatment is unknown. As a result, current clinical management is generally extrapolated from principles established for the treatment of female breast carcinoma. As the majority of male breast cancer patients have a hormone receptor positive tumor, they receive tamoxifen 20 mg for five years as standard endocrine adjuvant therapy. A lot of withdrawals from the treatment were documented in male breast cancer due to side-effects under tamoxifen therapy. Furthermore, the clinical outcome of tamoxifen-treated male breast cancer patients may be influenced by the activity of cytochrome P450 2D6 enzymes that catalyse the formation of anti-estrogenic metabolites endoxifen and 4-hydroxy-tamoxifen. Therefore a significant proportion of poor to moderate metaboliser is proposed to do not benefit from adjuvant tamoxifen therapy.

Although women benefit from adjuvant treatment with aromatase inhibitors (AI) regarding disease-free-survival, overall survival and treatment toxicity, only case reports of men treated with AI exist. Other data show, that under AI, there is only a suppression of estradiol of about 40-50% with an increase of testosterone of about 50%. Among men on AIs, it is possible that the hypothalamic-pituitary feedback loop results in an increase substrate for aromatisation, and thus prevents complete estrogen suppression.

However, an optimal suppression (80%) of the peripheral estradiol level would be a necessary condition for a therapeutic benefit of AI in men with breast cancer.

By adding a gonadotropin-releasing hormone analogue, the negative feedback loop would be interrupted and complete estrogen suppression may be achieved.

In conclusion, there is a great lack on information for the treatment of male patients with breast cancer.

Prospective multi-centre, randomised trials in men with breast cancer are necessary in order to prove the effect of tamoxifen + GnRH analogue versus none and versus AI + GnRH analogue as adjuvant or neoadjuvant endocrine treatment.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date May 2018
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 85 Years
Eligibility Inclusion criteria

1. Written informed consent for all study procedures.

2. Complete baseline documentation sent to GBG Forschungs GmbH.

3. Male patients.

4. Age = 18 years.

5. Karnofsky-Index = 60%.

6. Histologically confirmed unilateral or bilateral carcinoma or of the breast at primary diagnosis (enrolment possible in neoadjuvant, adjuvant and metastatic situation).

7: No target lesion necessary for metastatic situation 8. Positive hormone receptor status (e.g. ER and/or PR-receptor positive). 9. Completed staging prior randomisation ( within 8 weeks after diagnose or last therapy (operation, chemotherapy or radiation), minimum: chest X-ray, ultrasound of the liver, bone scan).

In case of positive findings, further investigations are required to verify the findings as clinically indicated.

10. Prior chemotherapy is possible. In case of adjuvant treatment: adequate surgical treatment with histological complete resection including axillary lymph nodes if patients are included as adjuvant treatment. A sentinel lymph node biopsy is possible if the sentinel is not involved.

11. Normal cardiac function must be confirmed by ECG within three months prior to randomisation.

12. Laboratory requirements (= 14 days before therapy start): Hematology

- Hemoglobin = 9 g/dL,

- Leukocytes 4 - 10 x1000/µL,

- Thrombocytes 150 - 400 x1000/µL. Hepatic function

- ASAT (SGOT) or ALAT (SGPT) = 2x UNL,

- Total bilirubin = 2x UNL. Renal function

- Serum creatinine = 1.5x UNL,

- Creatinine clearance > 30 mL/min (if creatinine is above UNL, according to Cockroft-Gault).

- Cholesterol 200 - 240 mg/dL (5.18 - 6.22 mmol/L),

- HDL cholesterol > 40 mg/dL (> 1 mmol/L),

- LDL cholesterol = 160 mg/dL (= 4 mmol/L).

- Prostate specific antigen (PSA) = 2.5 ng/mL. 13. Two serum samples (5 mL) centrally made available. 14. Paraffin tumor tissue block and full blood sample centrally made available (except when the patient does not agree to central biomaterial collection).

15. The patient must be accessible for treatment. Patients can simultaneously be registered in the register study of the University Hospital of Magdeburg.

Exclusion Criteria

1. Female patients.

2. Prior endocrine therapy of breast carcinoma.

3. Known or suspected hypersensitivity reaction to the compounds or incorporated substances.

4. No indication for endocrine treatment.

5. Life expectancy of less than six months.

6. International Prostate Symptom Score (IPSS) > 17.

7. Current diagnosis of a Prostate carcinoma.

8. History of prostate cancer within the last five years and regardless the time frame all patients with hormone receptor positive prostate carcinoma who have received endocrine treatment.

9. Concurrent neuronal or cardiac disease, poorly controlled arterial hypertension.

10. Previous thromboembolic event within the last five years (except from thromboembolic events correlated to implanted devices (e.g. port thrombosis)

11. Currently active hepatitis.

12. Disease significantly affecting gastrointestinal function, e.g. malabsorption syndrome, resection of the stomach or small bowel.

13. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry.

14. Patients who are not able to give informed consent as defined according to AMG.

Study Design


Intervention

Drug:
Tamoxifen
25 mg daily.
Tamoxifen and GnRH analogue
25 mg Tamoxifen daily and GnRH analogue: Goserelin (10.8 mg s.c. after randomisation and after three months) or Leuprorelin (11.25 mg s.c. after randomisation and after three months).
Exemestane and GnRH analogue
25 mg Exemestane daily and GnRH analogue: Goserelin (10.8 mg s.c. after randomisation and after three months) or Leuprorelin (11.25 mg s.c. after randomisation and after three months).

Locations

Country Name City State
Germany Kliniken Essen-Mitte Essen Nordrhein-Westfalen

Sponsors (2)

Lead Sponsor Collaborator
German Breast Group Pfizer

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Estradiol blood concentation To determine the estradiol suppression between the three treatment arms after three months. 3 months.
Secondary Estradiol blood concentration To determine the estradiol suppression between the three treatment arms after six months. 6 months.
Secondary Compliance To compare the compliance in the three treatment arms. 6 months.
Secondary Efficacy To compare the efficacy in terms of overall response (for neoadjuvant and metastatic patients) in the three treatment arms. 6 months.
Secondary Efficacy perameters To compare testosterone, dihydrotestosterone (DHT), SHBG, FSH, LH, osteocalcin and CTX in the three treatments arms. 6 months.
Secondary Safety and side effect parameters To determine the safety and side effect parameters (at every visit):
PSA and hemoglobin.
Lipids (total cholesterol, high density lipid cholesterol, low density lipid cholesterol).
6 months.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02480933 - Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens N/A
Terminated NCT01705340 - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1
Terminated NCT01222377 - Endoscopic Breast Surgery in Treating Patients With Breast Cancer N/A
Completed NCT00244881 - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) Phase 2
Completed NCT00425672 - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment Phase 1/Phase 2
Completed NCT00096434 - Sorafenib in Treating Patients With Metastatic Breast Cancer Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Active, not recruiting NCT00791037 - Vaccine Therapy in Treating Patients With Stage IV Breast Cancer Phase 1/Phase 2
Completed NCT00559507 - Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00119262 - Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer Phase 2
Completed NCT00098605 - Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases Phase 2
Terminated NCT00095888 - 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer Phase 2
Terminated NCT00071942 - Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Phase 1
Completed NCT00068588 - GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer Phase 2
Recruiting NCT05501704 - ETHAN - ET for Male BC Phase 2
Completed NCT01869764 - Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Phase 2
Completed NCT02046421 - Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Completed NCT01720602 - Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy N/A
Completed NCT01493310 - Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer Phase 1

External Links